Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07019844 · ClinicalTrials.gov registry record
PSMA PET for the Staging and Management of Hepatocellular Carcinoma
A clinical trial of Hepatocellular Carcinoma (HCC), sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- 90
- Enrollment target
- 1
- Study location
NCT07019844 is a study of Hepatocellular Carcinoma (HCC) that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 90 participants, below the 345-participant average among 15 other Hepatocellular Carcinoma (HCC) trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07019844, a study of Hepatocellular Carcinoma (HCC), is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
This prospective, single-center study evaluates the clinical utility of F18-Piflufolastat (PSMA) PET/CT when added to conventional cross-sectional imaging for patients with suspected or confirmed hepatocellular carcinoma (HCC). The study aims to determine whether PSMA PET/CT improves diagnostic accuracy for indeterminate liver lesions (LI-RADS 3 and 4), enhances staging precision in treatment-naïve patients, and provides more accurate assessment of treatment response in patients undergoing locoregional therapy (LRT). The goal is to assess how PSMA PET/CT may impact clinical decision-making, staging, and management of HCC across multiple stages of disease.
Conditions Studied
Study Locations (1)
Florida
- Miami VA Healthcare System, Miami, FL - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2024-09-19 |
| Est. Completion | 2028-09-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07019844
The ClinicalTrials.gov registry entry for NCT07019844 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 345-participant average among 15 other Hepatocellular Carcinoma (HCC) trials with a reported enrollment target (74% lower). The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatocellular Carcinoma (HCC) appearing as the primary indexed condition, and to 0 interventions.
NCT07019844 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT07019844 about?
NCT07019844 is a clinical study titled "PSMA PET for the Staging and Management of Hepatocellular Carcinoma". This prospective, single-center study evaluates the clinical utility of F18-Piflufolastat (PSMA) PET/CT when added to conventional cross-sectional imaging for patients with suspected or confirmed hepatocellular carcinoma (HCC). The study aims to determine whether PSMA PET/CT improves diagnostic accu...
What is the current status of trial NCT07019844?
This trial is currently recruiting. The enrollment target is 90 participants. The study started on 2024-09-19. Estimated completion is 2028-09-30.
What conditions does trial NCT07019844 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma (HCC).
Who is sponsoring clinical trial NCT07019844?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07019844 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma (HCC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
RECRUITING · Phase 1
-
The Dragon PLC Trial (DRAGON-PLC)
RECRUITING · NA
-
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
RECRUITING · Phase 1
-
A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer
RECRUITING
-
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.